• Corcept Therapeutics director James N. Wilson sold 10,000 common shares on Oct. 15, 2026.
• Sales comprised 6,654 shares at $114.4751, 3,046 at $115.3895 and 300 at $116.2967.
• The James N. Wilson and Pamela D. Wilson Trust held 1,054,543 common shares following the sales.
• Two grantor retained annuity trusts held another 400,000 common shares indirectly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-424350), on October 16, 2026, and is solely responsible for the information contained therein.